Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 4 of 4

Full-Text Articles in Medicine and Health Sciences

Detection Of Metastases Using Circulating Tumour Dna In Uveal Melanoma, Aaron B. Beasley, Daniël P. De Bruyn, Leslie Calapre, Zeyad Al-Ogaili, Timothy W. Isaacs, Jacqueline Bentel, Anna L. Reid, Roy S. Dwarkasing, Michelle R. Pereira, Muhammad A. Khattak, Tarek M. Meniawy, Michael Millward, Erwin Brosens, Annelies De Klein, Fred K. Chen, Emine Kiliҫ, Elin S. Gray Jan 2023

Detection Of Metastases Using Circulating Tumour Dna In Uveal Melanoma, Aaron B. Beasley, Daniël P. De Bruyn, Leslie Calapre, Zeyad Al-Ogaili, Timothy W. Isaacs, Jacqueline Bentel, Anna L. Reid, Roy S. Dwarkasing, Michelle R. Pereira, Muhammad A. Khattak, Tarek M. Meniawy, Michael Millward, Erwin Brosens, Annelies De Klein, Fred K. Chen, Emine Kiliҫ, Elin S. Gray

Research outputs 2022 to 2026

Background: Approximately 50% of uveal melanoma (UM) patients will develop metastatic disease depending on the genetic features of the primary tumour. Patients need 3–12 monthly scans, depending on their prognosis, which is costly and often non-specific. Circulating tumour DNA (ctDNA) quantification could serve as a test to detect and monitor patients for early signs of metastasis and therapeutic response. Methods: We assessed ctDNA as a biomarker in three distinct UM cohorts using droplet-digital PCR: (A) a retrospective analysis of primary UM patients to predict metastases; (B) a prospective analysis of UM patients after resolution of their primary tumour for early …


Assessment Of A Size-Based Method For Enriching Circulating Tumour Cells In Colorectal Cancer, Sai Shyam Vasantharajan, Edward Barnett, Elin S. Gray, John L. Mccall, Euan J. Rodger, Michael R. Eccles, Fran Munro, Sharon Pattison, Aniruddha Chatterjee Jul 2022

Assessment Of A Size-Based Method For Enriching Circulating Tumour Cells In Colorectal Cancer, Sai Shyam Vasantharajan, Edward Barnett, Elin S. Gray, John L. Mccall, Euan J. Rodger, Michael R. Eccles, Fran Munro, Sharon Pattison, Aniruddha Chatterjee

Research outputs 2022 to 2026

Circulating tumour cells (CTC) from solid tumours are a prerequisite for metastasis. Isolating CTCs and understanding their biology is essential for developing new clinical tests and precision oncology. Currently, CellSearch is the only FDA (U.S. Food and Drug Administration)-approved method for CTC enrichment but possesses several drawbacks owing to a reliance on the epithelial cell adhesion molecule (EpCAM) and a resource-intensive nature. Addressing these shortcomings, we optimised an existing size-based method, MetaCell, to enrich CTCs from blood of colorectal cancer (CRC) patients. We evaluated the ability of MetaCell to enrich CTCs by spiking blood with CRC cell lines and assessing …


Rankl/Rank Promotes The Migration Of Gastric Cancer Cells By Interacting With Egfr, Xing Wan, Yongxi Song, Honghong Fang, Ling Xu, Xiaofang Che, Shuo Wang, Xiaomeng Zhang, Lingyun Zhang, Ce Li, Yibo Fan, Kezuo Hou, Zhi Li, Xueqing Wang, Yunpeng Liu, Xiujuan Qu Jan 2020

Rankl/Rank Promotes The Migration Of Gastric Cancer Cells By Interacting With Egfr, Xing Wan, Yongxi Song, Honghong Fang, Ling Xu, Xiaofang Che, Shuo Wang, Xiaomeng Zhang, Lingyun Zhang, Ce Li, Yibo Fan, Kezuo Hou, Zhi Li, Xueqing Wang, Yunpeng Liu, Xiujuan Qu

Research outputs 2014 to 2021

BACKGROUND: The incidence and mortality rates of gastric cancer (GC) rank in top five among all malignant tumors. Chemokines and their receptor-signaling pathways reportedly play key roles in the metastasis of malignant tumor cells. Receptor activator of nuclear factor κB ligand (RANKL) is a member of the tumor necrosis factor family, with strong chemokine-like effects. Some studies have pointed out that the RANKL/RANK pathway is vital for the metastasis of cancer cells, but the specific mechanisms in GC remain poorly understood. RESULTS: This study reports original findings in cell culture models and in patients with GC. Flow cytometry and western …


Genetic Factors In Metastatic Progression Of Cutaneous Melanoma: The Future Role Of Circulating Melanoma Cells In Prognosis And Management, A Ireland, M Millward, R Pearce, M Lee, Mel Ziman Jan 2011

Genetic Factors In Metastatic Progression Of Cutaneous Melanoma: The Future Role Of Circulating Melanoma Cells In Prognosis And Management, A Ireland, M Millward, R Pearce, M Lee, Mel Ziman

Research outputs pre 2011

The greatest potential for improvement of outcome for patients with Cutaneous Malignant Melanoma lies in the prevention of systemic metastasis. Despite extensive investigation, current prognostic indicators either alone or in combination, although related to melanoma progression, are not sufficient to accurately predict the pattern of progression and outcome for any individual patient. Metastasis related death has been recorded in patients initially diagnosed with early stage tumour as well as in patients many years after initial tumour removal. The trouble finding a predictable pattern in the puzzle of melanoma progression may be linked to the fact that most of the material …